Climate Change Data

Environmental Metrics

ESG Focus Areas

• Environmental Impact
• People and Society
• Responsible Business

Environmental Achievements

• Reduced Scope 3 emissions by over 50% compared to 2023; Scope 2 emissions were 100% from renewable sources.

Social Achievements

• Sponsored overseas employee visa requirements to attract specific skills; New appointments to the IXICO Board broadened its knowledge, experience, and skill set; Supported staff in continued professional education and development via value-driven objective setting and performance review; A second cohort of leadership training was rolled out; Shareholder approval received for the adoption and implementation of IXICO’s 2024 EMI Share Option Plan.
• Continued growth of the HD-IH consortium with the onboarding of an additional bio-pharma partner. Significant progress in applying IXIQ.Ai to more than 6,000 MRI scans, demonstrating the utility of biomarker measurements as clinical trial endpoints. Preliminary findings presented at the annual HD-TC conference.

Governance Achievements

• Continued compliance with ISO 13845, GCP, and 21 CFR Part 11; GDPR training and refresher training; Investments in IXICO’s infrastructure and data governance program; Mandatory Anti-bribery training; Ongoing department-through-to-Board risk review, assessment, and monitoring program.

Climate Goals & Targets

Environmental Challenges

• Slowdown in clinical trial initiations; Tightening of the funding environment impacting the number of clinical trials initiated, particularly in the biotech sector; Threat of cyberattacks; Failure to attract and retain talent; IT infrastructure failures; Termination of client clinical trials; Insufficient cash reserves; Liquidity, credit, and currency risks; Failure to exploit commercial opportunities; Data protection risks.

Mitigation Strategies

• Early indications of a strengthening clinical trials market; Investments in Product Management, Marketing, and Business Development; Alignment of Science resources with commercial strategy; Webinars and conference participation; Continued investment in IT infrastructure, including cloud services; Ongoing review of potential vulnerabilities; Cybersecurity training; Deployment of security enhancements; Independent penetration tests; New CEO appointment; Framework to support employee objectives; Shareholder approval for 2024 IXICO EMI Share Option Plan; Initiatives to enhance employee engagement; Development and launch of next-generation TrialTracker platform; Continuing investments in infrastructure; All production servers hosted in secure data centers; External independent penetration tests; Focus on diversification of client and project pipelines; Commercial contracts with up-front payments and termination clauses; Client governance meetings and stakeholder engagement; Continued investment in the Group’s commercial team; Detailed budgets and forecasts; Negotiation of up-front payments with clients; Agile approach to react to changes; £4 million fundraise; Standard controls around financial risks; Currency hedges; Deposit accounts with banking partner; Change in CEO resulting in a clear strategy; Annual review by the Board of Group strategy and budget priorities; Monthly leadership review of strategic initiatives; Board appraisal of significant investments; External expertise and advice; Detailed qualification of client opportunities; Exploration of new revenue streams; Data captured from client sites is pseudonymised; Computerised systems compliance policies and procedures; Data protection legislation requirements integrated within the Group’s processing activities and practices; All employees undergo GDPR training and annual refresher training.

Supply Chain Management

Climate-Related Risks & Opportunities